Featured Trials

These Phase 2 and Phase 3 trials represent the most promising treatments currently being studied for mesothelioma.

PHASE2 NCT06543069

Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM

Enrolling: 28
View on ClinicalTrials.gov →
PHASE2 NCT06318286

Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma

Enrolling: 25
View on ClinicalTrials.gov →
PHASE2 NCT06840834

Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy

Enrolling: 38
View on ClinicalTrials.gov →
PHASE1/PHASE2 NCT05703854

Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

Enrolling: 50
View on ClinicalTrials.gov →
PHASE1/PHASE2 NCT05278975

Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

Enrolling: 186
View on ClinicalTrials.gov →
PHASE2 NCT06875076

Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma

Enrolling: 25
View on ClinicalTrials.gov →
PHASE2 NCT06057935

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

Enrolling: 64
View on ClinicalTrials.gov →
PHASE2 NCT05188859

First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma

Enrolling: 29
View on ClinicalTrials.gov →

Understanding Clinical Trials

Clinical trials test new treatments before they become widely available. For mesothelioma patients, trials often provide access to cutting-edge therapies that may be more effective than standard treatments.

Trial Phases Explained

Phase 1

Tests safety and dosing in a small group (15-30 patients). Focuses on finding the right dose with acceptable side effects.

23 trials

Phase 2

Tests effectiveness in a larger group (30-100 patients). Evaluates whether the treatment shows promise against the cancer.

19 trials

Phase 3

Compares new treatment to standard care (100-1000+ patients). Success here can lead to FDA approval.

2 trials

Treatment Categories

Immunotherapy

Treatments that help your immune system fight cancer, including checkpoint inhibitors like pembrolizumab and nivolumab.

32 trials

CAR-T Cell Therapy

Engineered immune cells designed to target mesothelin and other proteins on mesothelioma cells.

5 trials

Targeted Therapy

Drugs that target specific molecular pathways involved in mesothelioma growth.

6 trials

Chemotherapy

New chemotherapy combinations or delivery methods, often combined with immunotherapy.

15 trials

How to Enroll

  1. Talk to your oncologist — Discuss whether a clinical trial might be appropriate for your situation.
  2. Check eligibility — Each trial has specific criteria for who can participate.
  3. Contact the trial coordinator — Use the contact information on ClinicalTrials.gov.
  4. Understand the commitment — Trials may require additional visits, tests, and follow-up.